SCHEMBL30336151

SCHEMBL30336151

Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCc2cccc(Cl)c2F)cn1

nearest known ligand 0.71

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 0.71
CYP2C9 P11712 12/20 0.71
MAPK11 Q15759 3/20 0.71
BUB1 O43683 1/20 0.67
PRKACG P22612 1/20 0.67
MAPKAPK2 P49137 1/20 0.67
ACSL5 Q9ULC5 1/20 0.67
STK24 Q9Y6E0 1/20 0.67
MAPK13 O15264 2/20 0.46
CYP3A4 P08684 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3406993 1.00 MAPK14 (0.71) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3407001 0.93 MAPK14 (0.70) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL30335917 0.93 MAPK14 (0.70) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3406811 0.92 MAPK14 (0.71) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3412151 0.89 MAPK14 (0.74) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL28751623 0.89 MAPK14 (0.55) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3425121 0.88 MAPK14 (0.73) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3409936 0.88 MAPK14 (0.73) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL3535883 0.88 MAPK14 (0.73) MAPK14CYP2C9MAPK11BUB1PRKACG
SCHEMBL31079747 0.87 MAPK14 (0.72) MAPK14CYP2C9MAPK11BUB1PRKACG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114748622-B P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD 弗尔康医疗公司 2024-09-24 CN disclosed
EP-4159212-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2023-04-05 EP disclosed